Title 31 — Title 31
0 chapters · 651 sections in this title.
O.C.G.A. § 31-52-1 Short title
0.2K chars
This chapter shall be known and may be cited as the ‘‘Georgia Right to Try Act.’’ History. — Code 1981, § 31-52-1, enacted by Ga. L. 2016, p. 345, § 1/HB 34. 31-52-2. Legislative findings.
O.C.G.A. § 31-52-10 Statutory construction
1.6K chars
(a) This chapter shall not be construed to create a private cause of action against a manufacturer of an investigational drug, biological product, or device or against any other person or entity involved in the care of an eligible patient using an investigational drug, biological…
O.C.G.A. § 31-52-2 Legislative findings
1.4K chars
(a) The General Assembly finds and declares that: (1) The process of approval for investigational drugs, biological products, and devices in the United States protects future patients from premature, ineffective, and unsafe medications and treatments over the long run, but the pr…
O.C.G.A. § 31-52-3 Definitions
1.4K chars
As used in this chapter, the term: (1) ‘‘Eligible patient’’ means a person who meets the requirements of Code Section 31-52-4. (2) ‘‘Investigational drug, biological product, or device’’ means a drug, biological product, or device which has successfully completed Phase I of a fed…
O.C.G.A. § 31-52-4 Eligibility criteria
0.7K chars
In order for a person to be considered an eligible patient to access an investigational drug, biological product, or device pursuant to this chapter, a physician must document in writing that the person: (1) Has a terminal illness; 1015 31-52-5 (2) Has, in consultation with the p…
O.C.G.A. § 31-52-5 Written informed consent
4.4K chars
Written informed consent shall, at a minimum, include the following: (1) A description of the currently approved products and treatments for the terminal illness from which the patient suffers; (2) An attestation that the patient concurs with his or her physician in believing tha…
O.C.G.A. § 31-52-9 State prohibited from blocking eligible patient access
0.4K chars
No official, employee, or agent of the state shall block or attempt to block an eligible patient’s access to an investigational drug, biological product, or device. Counseling, advice, or a recommendation for treatment consistent with medical standards of care shall not be constr…